Baker Bros. Advisors LP Protagonist Therapeutics, Inc Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $5.9 Million - $22.6 Million	-455,276 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $25.1 Million - $44 Million	-980,916 Reduced 68.3%	455,276 $20.4 Million
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $2.96 Million - $4.02 Million	-160,006 Reduced 10.02%	1,436,192 $29 Million
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $4.79 Million - $7.06 Million	-315,248 Reduced 16.49%	1,596,198 $31.2 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $1.44 Million - $4.38 Million	232,282 Added 13.83%	1,911,446 $33.8 Million

Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $2.73 Million - $4.66 Million	504,882 Added 42.99%	1,679,164 $11.9 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $1.69 Million - $2.97 Million	179,200 Added 18.01%	1,174,282 $14.1 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $5.31 Million - $7.66 Million	591,189 Added 146.37%	995,082 $12.1 Million
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $2.63 Million - $5.56 Million	403,893 New	403,893 $5.08 Million

187

59.5M

35.7K

72.3K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.7B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.